Login / Signup

Predicting the public health impact of a malaria transmission-blocking vaccine.

Joseph D ChallengerDaniela Olivera MesaDari F DaRakiswendé Serge YerbangaThierry LefevreAnna CohuetThomas S Churcher
Published in: Nature communications (2021)
Transmission-blocking vaccines that interrupt malaria transmission from humans to mosquitoes are being tested in early clinical trials. The activity of such a vaccine is commonly evaluated using membrane-feeding assays. Understanding the field efficacy of such a vaccine requires knowledge of how heavily infected wild, naturally blood-fed mosquitoes are, as this indicates how difficult it will be to block transmission. Here we use data on naturally infected mosquitoes collected in Burkina Faso to translate the laboratory-estimated activity into an estimated activity in the field. A transmission dynamics model is then utilised to predict a transmission-blocking vaccine's public health impact alongside existing interventions. The model suggests that school-aged children are an attractive population to target for vaccination. Benefits of vaccination are distributed across the population, averting the greatest number of cases in younger children. Utilising a transmission-blocking vaccine alongside existing interventions could have a substantial impact against malaria.
Keyphrases
  • public health
  • clinical trial
  • physical activity
  • young adults
  • healthcare
  • aedes aegypti
  • mental health
  • plasmodium falciparum
  • dengue virus
  • zika virus
  • study protocol
  • electronic health record